- Home
- FENC vs SUNS Comparison
FENC vs SUNS Comparison
Compare FENC & SUNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FENC
- SUNS
- Stock Information
- Founded
- FENC 1996
- SUNS 2023
- Country
- FENC United States
- SUNS United States
- Employees
- FENC N/A
- SUNS N/A
- Industry
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- SUNS Real Estate Investment Trusts
- Sector
- FENC Health Care
- SUNS Real Estate
- Exchange
- FENC Nasdaq
- SUNS Nasdaq
- Market Cap
- FENC 156.9M
- SUNS 148.2M
- IPO Year
- FENC 2001
- SUNS N/A
- Fundamental
- Price
- FENC $5.53
- SUNS $10.90
- Analyst Decision
- FENC Strong Buy
- SUNS Strong Buy
- Analyst Count
- FENC 2
- SUNS 3
- Target Price
- FENC $14.00
- SUNS $13.92
- AVG Volume (30 Days)
- FENC 126.0K
- SUNS 179.3K
- Earning Date
- FENC 05-13-2025
- SUNS 03-06-2025
- Dividend Yield
- FENC N/A
- SUNS 8.54%
- EPS Growth
- FENC N/A
- SUNS N/A
- EPS
- FENC N/A
- SUNS 1.00
- Revenue
- FENC $47,538,000.00
- SUNS $10,588,270.00
- Revenue This Year
- FENC $2.68
- SUNS $141.80
- Revenue Next Year
- FENC $71.63
- SUNS $53.98
- P/E Ratio
- FENC N/A
- SUNS $11.07
- Revenue Growth
- FENC 123.69
- SUNS 1342.10
- 52 Week Low
- FENC $3.96
- SUNS $8.11
- 52 Week High
- FENC $11.29
- SUNS $15.74
- Technical
- Relative Strength Index (RSI)
- FENC 30.64
- SUNS N/A
- Support Level
- FENC $6.25
- SUNS N/A
- Resistance Level
- FENC $6.90
- SUNS N/A
- Average True Range (ATR)
- FENC 0.36
- SUNS 0.00
- MACD
- FENC -0.09
- SUNS 0.00
- Stochastic Oscillator
- FENC 4.20
- SUNS 0.00
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About SUNS Sunrise Realty Trust Inc. Common Stock
Sunrise Realty Trust Inc is a real estate investment trust company. It is focus on originating CRE debt investments and providing capital to high-quality borrowers and sponsors with transitional business plans collateralized by CRE assets with opportunities for near-term value creation, as well as recapitalization opportunities. It intends to create a diversified investment portfolio, targeting investments in senior mortgage loans, mezzanine loans, whole loans, B-notes, CMBS and debt-like preferred equity securities across CRE asset classes and investment mix to include high quality multi-family, condominiums, retail, office, hospitality, industrial, mixed use and specialty-use real estate.